The preclinical data presented at the Options conference showed broadly protective properties of VIS410 as an effective preventive and therapeutic investigational agent against influenza A subtypes. In the preclinical study, VIS410 had an additive effect when used in combination with anti-viral drugs in the treatment of influenza. These data build on the body of existing studies that have shown the efficacy of VIS410 against a broad range of influenza A strains, including H1N1, H5N1 and H3N2. Developed using Visterra's innovative technology, VIS410 is designed to be a broadly protective, fully human monoclonal antibody that targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes, and is resistant to mutation.
"VIS410 continues to demonstrate highly encouraging results across the spectrum of influenza A strains, and further supports Visterra's plans to develop VIS410 as a new universal approach to combat both seasonal and pandemic influenza," said Dr. Ambrosino.
"We are pleased to be among the global leaders in influenza at the Options conference and to be sharing the exciting results that suggest that VIS410 offers a novel approach to influenza and potential pandemic threats," said
Keywords for this news article include: Influenza, Pandemics, Epidemiology, Therapeutics,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- 15 Myths That Could Ruin Your Hispanic Ad Campaign
- Bitcoin Clones Lurch Onto Financial Scene
- General Motors Names Mary Barra as First Female CEO
- AIG to Create 230 Jobs in Charlotte
- Clinton to Keynote Annual Simmons Leadership Conference
- How Bitcoin and Other Cryptocurrencies Work
- Californians Want to Legalize Marijuana
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia
- Budget Deal Sets Off Grumbles in Both Houses
- Russia Says Nyet to Canada North Pole Claim